Latest News
NanoViricides, Inc.
- NanoViricides, Inc. Estimates – MUN:NV3P
- NanoViricides files prospectus for $2.375M common stock offering
- Form 424B5 NanoViricides Inc For: 21 October By Investing.com
- NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
- Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
- Form DEF 14A NANOVIRICIDES For: 8 October By Investing.com
- NanoViricides to Present at NIBA Conference as NV-387 Advances in Ebola and Mpox Trials
- NanoViricides Advances Phase II Trial of Oral Ebola Treatment as Congo Outbreak Continues
- NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
- NanoViricides, Inc. (NNVC) Files 10-K; NV-387 Enters Phase II Trials
- NanoViricides: Fiscal Q4 Earnings Snapshot
- NANOVIRICIDES, INC. FY 2026: Revenue $0 EPS ($0.41) — 10-K Summary
Headlines from the last 30 days, linking to the original publishers. See all market news →